Yat Sun Or - 25 Nov 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ENTA
Reported as of: 25 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Nov 2025, 17:03:25 UTC
Prior SEC filing: 14 Feb 2025
Next SEC filing: 03 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Kowalsky as attorney-in-fact

Key filing fact

Yat Sun Or filed Form 4 for ENANTA PHARMACEUTICALS INC (ENTA) on 26 Nov 2025.

Key facts

This page summarizes Yat Sun Or's Form 4 filing for ENANTA PHARMACEUTICALS INC (ENTA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Nov 2025, 17:03.

Change

Previous filing in this sequence was filed on 14 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001571212 Primary reporting owner

Or Yat Sun

Relationship: Chief Scientific Officer
Address: C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Signature date: 26 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENTA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +110,000
Change %
Price: $0.000000
Shares after: 110,000
Date: 25 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 110,000
Exercise price: $13.66
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).